Drug intelligence / Profile preview

CE211NS21

Development stage: Phase 1
Lead developer: Corestemchemon
Modality: Stem Cell Therapies → Cell Therapies

Overview

CE211NS21 is an investigational allogeneic bone marrow-derived mesenchymal stem cell (Allo BM-MSC) therapy currently in preclinical development by Corestemchemon for the treatment of Neuromyelitis Optica (NMO). NMO is a rare and debilitating autoimmune disease characterized by inflammation of the optic nerve and spinal cord. The therapy is designed to utilize the immunomodulatory and regenerative potential of mesenchymal stem cells to reduce neuroinflammation and promote tissue repair. Corestemchemon, a South Korean biotechnology company, is leveraging its experience with its approved ALS stem cell therapy, Neuronata-R, to advance CE211NS21 through the pipeline.

Beyond the preview

Go deeper on CE211NS21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CE211NS21.

Explore the full profile